OBJECTIVES: To investigate the relationship between Clostridium (Clostridioides) difficile strain characteristics and C. difficile infection (CDI) outcome. METHODS: Between October and December 2017, 16 hospitals collected epidemiological data according to the European Centre for Disease Prevention and Control (ECDC) surveillance protocol for CDI. C. difficile isolates were characterized by ribotyping, toxin genes detection and antibiotic susceptibility testing to metronidazole, vancomycin and moxifloxacin. RESULTS: The overall mean CDI incidence density was 4.5 [95% CI 3.6-5.3] cases per 10,000 patient-days. From the 433 CDI cases, 330 (76.2%) were healthcare-associated, 52 (12.0%) cases were community-associated or of unknown origin and 51 (11.8%) CDI cases recurrent; a complicated course of CDI was reported in 65 cases (15.0%). Eighty-eight (20.3%) of patients died and 59 of them within 30 days after the CDI diagnosis. From the 379 C. difficile isolates, the most prevalent PCR ribotypes were 001 (n = 127, 33.5%) and 176 (n = 44, 11.6%). A total of 186 (49.1%) isolates showed a reduced susceptibility to moxifloxacin (> 4 mg/L) and 96.4% of them had Thr82Ile in the GyrA. Nineteen isolates revealed reduced susceptibility to metronidazole and two isolates to vancomycin (> 2 mg/L). A fatal outcome was associated with a reduced susceptibility to moxifloxacin, the advanced age of the patients and a complicated course of CDI (p<0.05). No association between ribotype, binary toxin and a reduced susceptibility to moxifloxacin and complicated course or recurrent CDI was found. CONCLUSIONS: A reduced susceptibility to moxifloxacin, in causative C. difficile strains was associated with fatal outcome of the patients, therefore it is an important marker in surveillance of CDI.

Bioinformatics centre 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Clinical Microbiology and Parasitology Hospital Pribram Pribram Czech Republic

Department of Clinical Microbiology Hospital Nove Mesto na Morave Nove Mesto na Morave Czech Republic

Department of Clinical Microbiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Clinical Microbiology Military University Hospital Prague Czech Republic

Department of Clinical Microbiology University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Medical Microbiology and Immunology Hospital Liberec Liberec Czech Republic

Department of Medical Microbiology Charles University 2nd Faculty of Medicine and Motol University Hospital Prague Czech Republic

Department of Medical Microbiology Faculty of Medicine Charles University and University Hospital Plzen Plzen Czech Republic

Department of Medical Microbiology Faculty of Medicine Masaryk University and St Anne's University Hospital Brno Czech Republic

Department of Medical Microbiology Hospital Bulovka Prague Czech Republic

Department of Medical Microbiology Hospital Ceske Budejovice Ceske Budejovice Czech Republic

Department of Medical Microbiology Hospital Jindrichuv Hradec Jindrichuv Hradec Czech Republic

Department of Medical Microbiology Hospital Tabor Tabor Czech Republic

Department of Medical Microbiology Thomayer's Hospital Prague Czech Republic

Department of Medical Microbiology University Hospital Brno Brno Czech Republic

Department of Microbiology Faculty of Medicine and Dentistry Palacky University Hospital Olomouc Czech Republic

Zobrazit více v PubMed

Oren A, Rupnik M. Clostridium difficile and Clostridioides difficile: two validly published and correct names. Anaerobe. 2018;52:125–6. 10.1016/j.anaerobe.2018.07.005. PubMed

European Centre for Disease Prevention and Control . Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC; 2013.

Krutova M, Kinross P, Barbut F, Hajdu A, Wilcox MH, Kuijper EJ, Survey contributors. How to: surveillance of Clostridium difficile infections. Clin Microbiol Infect. 2018;24(5):469–75. 10.1016/j.cmi.2017.12.008. PubMed

Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1–26. 10.1111/1469-0691.12418. PubMed

Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Golubchik T, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017;17(4):411–21. 10.1016/S1473-3099(16)30514-X. PubMed DOI PMC

van Dorp SM, Kinross P, Gastmeier P, Behnke M, Kola A, Delmée M, et al. Standardised surveillance of Clostridium difficile infection in European acute care hospitals: a pilot study, 2013. Euro Surveill. 2016;21(29). 10.2807/1560-7917.ES.2016.21.29.30293. PubMed DOI

European Centre for Disease Prevention and Control. Clostridium difficile infections. In: ECDC. Annual epidemiological report for 2016. Stockholm: ECDC; 2018.

European Centre for Disease Prevention and Control . European Surveillance of Clostridium difficile infections. Surveillance protocol version 2.3. Stockholm: ECDC; 2017.

Institute of health information and statistics of the Czech Republic (UZIS). Inpatient care. Prague: UZIS. Czech. Available from: https://www.uzis.cz/publikace/luzkovy-fond-2017. [Accessed 19 Sept 2019].

Crobach MJ, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22(Suppl 4):S63–81. 10.1016/j.cmi.2016.03.010. PubMed

Fawley WN, Knetsch CW, MacCannell DR, Harmanus C, Du T, Mulvey MR, et al. Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile. PLoS One. 2015;10(2):e0118150. 10.1371/journal.pone.0118150. PubMed DOI PMC

Persson S, Torpdahl M, Olsen KE. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect. 2008;14(11):1057–1064. doi: 10.1111/j.1469-0691.2008.02092.x. PubMed DOI

Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother. 2002;46(11):3418–3421. doi: 10.1128/AAC.46.11.3418-3421.2002. PubMed DOI PMC

Core Team R. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. https://www.R-project.org.

Krutova M, Matejkova J, Kuijper EJ, Drevinek P, Nyc O. Czech Clostridium difficile study group. Clostridium difficile PCR ribotypes 001 and 176 – the common denominator of C. difficile infection epidemiology in the Czech Republic, 2014. Euro Surveill. 2016;21(29). 10.2807/1560-7917.ES.2016.21.29.30296. PubMed

Krutova M, Matejkova J, Drevinek P, Kuijper EJ, Nyc O, study group. Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015. Eur J Clin Microbiol Infect Dis. 2017;36(11):2251–8. 10.1007/s10096-017-3055-z. PubMed

Ooijevaar RE, van Beurden YH, Terveer EM, Goorhuis A, Bauer MP, Keller JJ, Mulder CJJ, Kuijper EJ. Update of treatment algorithms for Clostridium difficile infection. Clin Microbiol Infect. 2018;24(5):452–62. 10.1016/j.cmi.2017.12.022. PubMed

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–94. 10.1093/cid/ciy149. PubMed

Freeman J, Vernon J, Pilling S, Morris K, Nicholson S, Shearman S, et al. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014. Clin Microbiol Infect. 2018;24(7):724–31. 10.1016/j.cmi.2017.10.008. PubMed

Vernon JJ, Wilcox MH, Freeman J. Effect of fluoroquinolone resistance mutation Thr-82→Ile on Clostridioides difficile fitness. J Antimicrob Chemother. 2019;74(4):877–84. 10.1093/jac/dky535. PubMed

He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, Connor TR, Harris SR, Fairley D, Bamford KB, D'Arc S, Brazier J, Brown D, Coia JE, Douce G, Gerding D, Kim HJ, Koh TH, Kato H, Senoh M, Louie T, Michell S, Butt E, Peacock SJ, Brown NM, Riley T, Songer G, Wilcox M, Pirmohamed M, Kuijper E, Hawkey P, Wren BW, Dougan G, Parkhill J, Lawley TD. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45(1):109–13. 10.1038/ng.2478. PubMed PMC

Eyre DW, Davies KA, Davis G, Fawley WN, Dingle KE, De Maio N, Karas A, Crook DW, Peto TEA, Walker AS, Wilcox MH, EUCLID Study Group. Two distinct patterns of Clostridium difficile diversity across Europe indicating contrasting routes of spread. Clin Infect Dis. 2018;67(7):1035–44. 10.1093/cid/ciy252. PubMed PMC

Rao K, Micic D, Natarajan M, Winters S, Kiel MJ, Walk ST, Santhosh K, Mogle JA, Galecki AT, LeBar W, Higgins PD, Young VB, Aronoff DM. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis. 2015;61(2):233–41. 10.1093/cid/civ254. PubMed PMC

Inns T, Gorton R, Berrington A, Sails A, Lamagni T, Collins J, Perry J, Hill K, Magee J, Gould K. Effect of ribotype on all-cause mortality following Clostridium difficile infection. J Hosp Infect. 2013;84(3):235–41. 10.1016/j.jhin.2013.04.008. PubMed

Berry CE, Davies KA, Owens DW, Wilcox MH. Is there a relationship between the presence of the binary toxin genes in Clostridium difficile strains and the severity of C. difficile infection (CDI)? Eur J Clin Microbiol Infect Dis. 2017;36(12):2405–15. 10.1007/s10096-017-3075-8. PubMed

Krutova M, Matejkova J, Nyc O. C. difficile ribotype 027 or 176? Folia Microbiol. 2014;59(6):523–6. 10.1007/s12223-014-0323-5. PubMed

Walker AS, Eyre DW, Wyllie DH, Dingle KE, Griffiths D, Shine B, Oakley S, O'Connor L, Finney J, Vaughan A, Crook DW, Wilcox MH, Peto TE. Infections in Oxfordshire research database. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis. 2013;56(11):1589–600. 10.1093/cid/cit127. PubMed PMC

Reigadas E, Alcalá L, Marín M, Martín A, Iglesias C, Bouza E. Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting. Epidemiol Infect. 2016;144(2):268–273. doi: 10.1017/S095026881500148X. PubMed DOI

Camins BC, Marschall J, DeVader SR, Maker DE, Hoffman MW, Fraser VJ. The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia. J Hosp Med. 2011;6(6):344–9. 10.1002/jhm.877. PubMed PMC

Goldstein E, MacFadden DR, Karaca Z, Steiner CA, Viboud C, Lipsitch M. Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states. Int J Antimicrob Agents. 2019;54(1):23–34. 10.1016/j.ijantimicag.2019.03.004. PubMed PMC

Genomic islands and molecular mechanisms relating to drug-resistance in Clostridioides (Clostridium) difficile PCR ribotype 176

Detection of Plasmid-Mediated Resistance to Metronidazole in Clostridioides difficile from River Water

Effect of Restriction of Fluoroquinolone Antibiotics on Clostridioides difficile Infections in the University Hospital Hradec Králové